Key Narmafotinib Patent Granted in the U.S.

Rhea-AI Summary

Amplia Therapeutics (OTCQB:INNMF) received a Certificate of Grant from the US Patent and Trademark Office for a patent titled A salt and crystal form of a FAK inhibitor, extending protection for the company's clinically developed FAK inhibitor narmafotinib to at least 2040 in the US and other jurisdictions. The grant follows a September 2025 notification of allowance and complements existing patents already granted in Europe, Japan, India, Korea and Australia. The patent specifically protects the particular salt/crystal form of narmafotinib being developed clinically. The company stated protection in additional regions is under review by respective patent offices and said the grants strengthen narmafotinib's long-term intellectual property position.

Positive

• US patent granted for narmafotinib salt/crystal form to 2040
• Existing patents granted in Europe, Japan, India, Korea, Australia
• Patent grant follows USPTO allowance notification in September 2025

Negative

• Patent covers a specific salt/crystal form, limiting claim breadth
• Protection in other regions remains under review and uncertain

News Market Reaction

-9.71%

1 alert

-9.71% News Effect

On the day this news was published, INNMF declined 9.71%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Patent protection horizon: at least 2040 Notification of allowance date: September 2025 Current price: $0.07665 +5 more

8 metrics

Patent protection horizon at least 2040 Narmafotinib patent coverage in US, Europe, Japan, India, Korea, Australia

Notification of allowance date September 2025 USPTO notification preceding Certificate of Grant

Current price $0.07665 Pre-news market context for INNMF

24h price change -46.42% Price move ahead of or around the patent news

52-week high $0.2724 Upper bound of last 52 weeks

52-week low $0.025 Lower bound of last 52 weeks

20-day avg volume 59,344 shares Liquidity benchmark vs today’s 560 shares

Price reaction to news -9.71% 24h move after this patent headline

Market Reality Check

Price: $0.1000 Vol: Volume 560 vs 20-day aver...

low vol

$0.1000 Last Close

Volume Volume 560 vs 20-day average 59,344 (relative volume 0.01x) indicates very light trading ahead of this news. low

Technical Price $0.07665 is trading below the 200-day MA of $0.09 and 71.86% below the 52-week high.

Historical Context

1 past event · Latest: Dec 03 (Positive)

Pattern 1 events

Date	Event	Sentiment	Move	Catalyst
Dec 03	Patent grant news	Positive	-9.7%	US and global patent grant extending narmafotinib protection to at least 2040.

Pattern Detected

The only recent event is this patent grant, which saw a negative price reaction despite being structurally positive for IP protection.

Recent Company History

Over the last six months, the only recorded news event for Amplia Therapeutics is the US and multi-jurisdiction patent grant for its FAK inhibitor narmafotinib on Dec 03, 2025. The patent extends protection to at least 2040 across the US, Europe, Japan, India, Korea and Australia and strengthens the company’s intellectual property around the clinically developed form of narmafotinib. Despite this positive development, the stock showed a -9.71% 24-hour reaction to the announcement.

Market Pulse Summary

The stock moved -9.7% in the session following this news. A negative reaction despite positive paten...

Analysis

The stock moved -9.7% in the session following this news. A negative reaction despite positive patent news fits the prior pattern, where this same announcement saw a -9.71% 24-hour move. The market context showed shares at $0.07665, far below the $0.2724 52-week high and trading below the $0.09 200-day MA, suggesting a weak backdrop. Limited liquidity, with average volume around 59,344 shares versus very light recent trading, could have amplified downside moves.

Key Terms

us patent and trademark office, fak inhibitor, patent, intellectual property

4 terms

us patent and trademark office regulatory

"received formal notification from the US Patent and Trademark Office (USPTO)"

The U.S. Patent and Trademark Office is the federal agency that reviews and issues patents for inventions and registers trademarks for brand names and logos, acting like a public property registry for ideas and brands. For investors, those issued patents and trademarks can create legal protection that helps a business keep competitors out, support pricing power or licensing revenue, and materially affect a company’s future profits and risk profile.

fak inhibitor medical

"a key patent for the FAK inhibitor narmafotinib"

A FAK inhibitor is a drug that blocks focal adhesion kinase, a protein that acts like a molecular switch helping cells stick, move and grow. By turning that switch down, these drugs can slow tumor spread or alter disease processes. Investors watch FAK inhibitors because their success or failure in clinical trials and regulation affects potential market value, partnerships and the commercial outlook for companies developing them—like backing a traffic-control device that could prevent crashes.

patent regulatory

"a key patent titled A salt and crystal form of a FAK Inhibitor has been granted"

A patent is a government-granted right that gives an inventor exclusive control to make, use, sell or license a specific invention for a limited time, usually in exchange for publicly describing how it works. For investors it matters because a patent can act like a time-limited lock on a product or process — reducing competition, protecting future sales or licensing income, and often increasing a company’s value, while still being defeasible, time-bound and subject to legal challenge.

intellectual property financial

"to protect and maximize the Company’s intellectual property for the long term"

Intellectual property are legal rights that protect creations of the mind—such as inventions, brand names, designs, software, or secret formulas—giving the owner control over who can use, copy or sell them. For investors, IP is like owning a blueprint or recipe: it can generate steady income through exclusive sales or licensing, boost a company’s competitive edge and valuation, and also create costs or risks if rights must be defended or challenged in court.

AI-generated analysis. Not financial advice.

Highlights

• The Company has received a Certificate of Grant from the US Patent and Trademark Office for a key patent for the FAK inhibitor narmafotinib
• The patent extends protection for narmafotinib to at least 2040

Melbourne, Australia, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX; OTCQB:INNMF), (“Amplia” or the “Company”), announces that it has received formal notification from the US Patent and Trademark Office (USPTO) that a key patent titled A salt and crystal form of a FAK Inhibitor has been granted. The Certificate of Grant follows on from the notification of allowance of the patent from the USPTO received in September¹.

This key patent protects the specific form of narmafotinib being developed clinically by the Company. The patent has already been granted in various important jurisdictions including Europe, Japan, India, Korea and Australia. Granting of this patent extends protection of narmafotinib out to a least 2040 in these jurisdictions. Protection in other regions is under review by the respective patent offices.

Amplia CEO Dr Chris Burns says, “With the granting of this patent in the US and other key pharmaceutical markets, we are strengthening narmafotinib’s patent portfolio to protect and maximize the Company’s intellectual property for the long term.”

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on X (@ampliatx) and LinkedIn.

About Narmafotinib

Narmafotinib (AMP945) is the company’s best-in-class inhibitor of the protein FAK, a protein over-expressed in pancreatic cancer and a drug target gaining increasing attention for its role in solid tumors. The drug, which is a highly potent and selective inhibitor of FAK, has shown promising data in a range of preclinical cancer studies. Narmafotinib is currently undergoing a clinical trial (the ACCENT trial) where it is dosed in combination with the chemotherapies gemcitabine and Abraxane in first-line patients with advanced pancreatic cancer. The trial has already achieved its primary endpoint in achieving a confirmed response rate of 33%, superior to 23% reported in the benchmark MPACT study for gemcitabine and Abraxane alone. An interim median PFS of 7.6 months has also been reported. A second trial – AMPLICITY – has recently opened and is being run under an IND at sites in Australia and the US, investigating the combination of narmafotinib with the chemotherapy FOLFIRINOX in advanced pancreatic cancer patients.

¹ASX Announcement, 30 September 2025

Investor Contact:
Dr Chris Burns
Chief Executive Officer
chris@ampliatx.com 

U.S. Contact:
Robert Giordano
rjgiordano@ggrouplifesciences.com 
+1 917 327 3938

Media Contact:
H^CK Director, Haley Chartres
haley@hck.digital 
+61 423 139 163

U.S. Media:
media@ampliatx.com

FAQ

What did Amplia Therapeutics (INNMF) announce on December 3, 2025 about narmafotinib?

Amplia announced a US patent grant for a salt and crystal form of narmafotinib, extending protection to at least 2040.

How long does the new US patent protect narmafotinib for INNMF shareholders?

The granted US patent extends protection for narmafotinib to at least 2040.

Which other jurisdictions already granted the narmafotinib patent for INNMF?

Patents for the same form have been granted in Europe, Japan, India, Korea and Australia.

Does the US patent cover all forms of narmafotinib for INNMF?

No; the patent specifically protects a salt and crystal form of narmafotinib being developed clinically.

What is the significance of the USPTO Certificate of Grant for INNMF investors?

The Certificate formalizes US protection for the drug form and bolsters the company's long-term intellectual property position.

Are patents for narmafotinib pending in other regions for INNMF?

Yes; the company said protection in other regions is currently under review by respective patent offices.